By Gareth MacDonald

Biobetters stand a better chance of winning market share than lower cost biosimilars in some indications according to new analysis.

Read more at http://www.biopharma-reporter.com/Product-News/Bio-Outsourcing/Biobetters-may-fare-better-than-biosimilars-in-some-therapeutic-areas-says-analyst